Intro
Nephrology has, for a long time, taught patients a hard lesson.
When the kidneys begin to lose function — when the eGFR starts to drift down, when creatinine starts to rise, when chronic kidney disease is named on a chart — the standard message is that the damage is largely irreversible. The goals shift to slowing the decline, managing complications, and preparing for what comes next.
That message has been delivered with care, and it has been delivered honestly, given what the field has historically understood. But there is a part of the kidney story that the standard message has not been able to account for.
The part where the kidney is being injured by something the liver is exporting.
And once that part comes into view, the trajectory looks different.
---
Meet the Podocyte
The kidney filters blood through tiny structures called glomeruli. Each glomerulus is a tuft of capillaries wrapped in a specialized cell called a podocyte.
Podocytes are not bystanders. They build the filtration barrier. They wrap their long, branching foot processes around the capillaries and create the slits that allow water and small molecules through while holding back proteins and larger structures. The integrity of those slits is the integrity of the filter.
Podocytes are also vulnerable. They do not divide easily. Once a podocyte is lost, it is not readily replaced. Lose enough of them and the filter starts to leak — protein appears in the urine, the glomerulus scars, and the eGFR begins its decline.
For decades, the question has been: what is killing the podocytes?
A growing body of work points to the same answer the rest of this series has been pointing at.
The lipid environment.
---
What the Lipid Environment Does to a Podocyte
When triglyceride-rich lipoproteins are circulating at elevated levels for sustained periods, the lipid load reaches the podocyte. Excess fatty acids accumulate inside the cell. Lipid droplets form where they should not. The cellular machinery — mitochondria, endoplasmic reticulum, the actin cytoskeleton that gives the podocyte its shape — begins to malfunction.
Inflammation follows. Oxidative stress follows. Insulin signaling inside the podocyte itself becomes impaired. The cell that built the filter is now being asked to function as a fat storage depot, and it is not built for that work.
This process has a name in the literature. It is called podocyte lipotoxicity.
It is no longer a fringe hypothesis. The mechanism has been described in cell culture, in animal models, in human kidney biopsies. The cells that maintain the filtration barrier are being injured by the lipid environment they are exposed to. And the lipid environment is being set, in significant part, by what the liver is exporting.
---
What the Population Data Show
If this mechanism is real, the population data should reflect it. They do.
A study of more than 911,000 individuals in the United Kingdom looked at which lipid markers predicted the onset of advanced chronic kidney disease. The findings were striking. Elevated triglycerides and reduced HDL-C were independently associated with progression to advanced CKD. Total cholesterol and LDL-C were not.
The cardiology lens that has dominated lipid management for forty years did not pick up the kidney signal. The triglyceride-and-HDL signal — the signature of what the liver is doing — did.
Other large cohorts agree. The Korean KNOW-CKD study found that serum triglycerides independently predicted adverse renal outcomes in non-dialysis CKD. NHANES data spanning two decades show that the triglyceride-glucose index — the same crude proxy for hepatic state we discussed in the last post — strongly predicts CKD prevalence.
The numbers that reflect what the liver is doing are the numbers that predict what happens to the kidney.
---
The Reframe
This is the move the kidney story makes possible.
The kidney is not failing on its own. In a meaningful number of cases, it is being injured by what the liver is exporting. The podocyte is paying a bill the liver has been writing.
This does not mean every case of CKD is a hepatic story. There are kidney diseases driven by autoimmunity, by genetics, by direct toxic injury, by uncontrolled blood pressure, by structural disease. The kidney has its own pathologies that have nothing to do with the liver.
But for the very large population of patients in whom CKD develops alongside metabolic dysfunction — alongside elevated triglycerides, low HDL, insulin resistance, hepatic steatosis — the kidney story and the liver story are not two diseases. They are one cascade with two organs in it.
And that changes what is possible.
---
The Reversibility Window
The standard message about CKD irreversibility is built on a model in which the kidney is the seat of the disease. When the kidney is treated as the source, the only options are to slow the decline that is already underway.
When the kidney is treated as downstream of an upstream lipid-export problem, a different option appears. If the upstream problem is addressed — if the hepatic state that has been producing the lipotoxic environment is improved — the stress on the podocyte is reduced. And there is now a real and growing body of evidence suggesting that, especially in earlier stages, the trajectory can change.
Fibrate trials have shown reduction in albuminuria progression and even regression in diabetic populations. Mechanistic work in model organisms has shown that increasing fatty acid flux through the proper triglyceride compartment protects the cellular machinery of renal cells. The acute creatinine bumps that fibrates sometimes produce, which have historically triggered concern, are now understood to reflect tubular handling rather than renal injury.
This is not a claim that CKD is universally reversible. It is not a promise that any specific patient's eGFR will rise. The evidence for trajectory change is strongest in earlier stages of CKD; in advanced disease, the structural damage that has accumulated places real limits on what is recoverable. The evidence does not support the level of certainty that would let us promise more, and we should not pretend otherwise.
But it is a claim that the trajectory is more modifiable than the field has historically held — and that the modification starts upstream, at the liver, with the signal that VLDL has been quietly reporting all along.
---
What This Post Is Asking You to Do
If you have a patient, or you are a patient, with a rising creatinine and a slowly drifting eGFR — and you also have elevated triglycerides, low HDL, signs of insulin resistance, or imaging suggestive of hepatic steatosis — the kidney number and the liver number are probably part of the same story.
Treating the kidney number alone, without addressing the upstream hepatic state, is treating a symptom while the cause continues to write the bill.
The next post will look at another tissue that has been paying that same bill, in its own way, for a long time.
The brain.